

North Central Cancer Treatment Group

N078D, Phase I/II Trial of Rituximab, Cladribine, and Temsirolimus (RCT) Therapy in Newly Diagnosed Mantle Cell Lymphoma (MCL)

Status Change – July 31, 2009

NOTICE OF STATUS CHANGE

This study will temporarily close to accrual effective immediately Friday, July 31, 2009 for safety assessment of the three patients enrolled at dose level 1, per study design.

Please retain this notice with the protocol.